A Study of LY3437943 in Participants Who Have Obesity or Are Overweight

  • End date
    Sep 28, 2022
  • participants needed
  • sponsor
    Eli Lilly and Company
Updated on 12 September 2021
cardiovascular disease
body mass index


This is a study of LY3437943 in participants who have obesity or are overweight. The main purpose is to learn more about how LY3437943 affects body weight loss. The study will last about 18 months and may include up to 18 visits.

Condition adiposity, Overweight, Obesity
Treatment Placebo, LY3437943
Clinical Study IdentifierNCT04881760
SponsorEli Lilly and Company
Last Modified on12 September 2021


Yes No Not Sure

Inclusion Criteria

Participants must have a Body Mass Index (BMI) ) 30 and 50 kilograms per square meter (kg/m), or 27 kg/m and <30 kg/m, with at least one of the following comorbidities: hypertension, dyslipidemia, cardiovascular disease
Participants must be willing to learn how to self-inject study drug or receive an injection from a trained individual if visually impaired or with physical limitations, and follow study procedures for the duration of the study, including, but not limited to, follow lifestyle advice (for example, dietary changes and physical activity plan), maintain a study drug administration log, and complete required questionnaires

Exclusion Criteria

Participants must not have type 1 or type 2 diabetes mellitus
Participants must not have had an increase or decrease in body weight > more than 5 kg (11 pounds) within the past 3 months
Participants must not have had surgery for obesity or plan to have such surgery during the study
Participants must not be using medications that promote weight loss or cause weight gain
Participants must not drink excessive amounts of alcohol (more than 14 units a week for women or more than 21 units a week for men)
Participants must not have used marijuana within the last 3 months
Participants must not have heart attack, stroke, or hospitalization for congestive heart failure in the past 3 months
Participants must not have active cancer within the last 5 years
Participants must not have uncontrolled high blood pressure
Participants must not have liver disease other than non-alcoholic fatty liver disease
Participants must not have renal impairment with estimated glomerular filtration rate (eGFR) <45 mL/min/1.73 m2
Participants must not have a history of acute or chronic pancreatitis symptomatic gallbladder disease or documented human immunodeficiency virus infection
Participants must not have a major problem with depression or other mental illness within the last 2 years
Participants must not have family or personal history of multiple endocrine neoplasia type 2 or medullary thyroid carcinoma (family is defined as a first degree relative)
Female participants must not be pregnant, breast-feeding, or intend to become pregnant or of childbearing potential and not using adequate contraceptive method (adequate contraceptive measures as required by local regulation or practice)
Clear my responses

How to participate?

Step 1 Connect with a site
What happens next?
  • You can expect the study team to contact you via email or phone in the next few days.
  • Sign up as volunteer to help accelerate the development of new treatments and to get notified about similar trials.

You are contacting

Investigator Avatar

Primary Contact


Preferred Language
Other Language
Please verify that you are not a bot.

Additional screening procedures may be conducted by the study team before you can be confirmed eligible to participate.

Learn more

If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.

Learn more

Complete your scheduled study participation activities and then you are done. You may receive summary of study results if provided by the sponsor.

Learn more

Similar trials to consider


Browse trials for

Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Sign up as volunteer

user name

Added by • 



Reply by • Private

Lorem ipsum dolor sit amet consectetur, adipisicing elit. Ipsa vel nobis alias. Quae eveniet velit voluptate quo doloribus maxime et dicta in sequi, corporis quod. Ea, dolor eius? Dolore, vel!

  The passcode will expire in None.

No annotations made yet

Add a private note
  • abc Select a piece of text from the left.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.
Add a private note